ProShares Ultra NASDAQ Biotechnology (BIB)
Price trend is one of its highest-scoring factors — company finances score (revenue, margins, returns) is near the top of its range, while score for how it compares with the broader market is above the middle.
BIB scores higher than 98% of the 5,674 tickers we compare it with (Funds & ETFs).
As of 10 October 2026, ProShares Ultra NASDAQ Biotechnology (BIB) scores 68 out of 100 on the Market Census six-factor composite, which puts it at the Above average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.89× 30-day average
- 52-week range
- 62.72 – 126.40
- Market cap
- —
- Earnings date
- —
- Volume
- 7,447
- Avg. volume (30d)
- 8,407
- Open
- 107.65
- Previous close
- 105.02
- Day's range (regular session)
- 106.78 – 111.36
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 1.27
- P/E (TTM)
- —
- EPS (TTM)
- —
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about BIB right now
ProShares Ultra NASDAQ Biotechnology (BIB) currently scores 68/100 on the Market Census six-factor composite, at the Above average score level. BIB is +5.68% on the day and +1.07% over five sessions as of the most recent tick. Above average sits a bit above the middle. The data for BIB leans good, with some weak spots. BIB's strongest factor is price trend at 95/100 — a very strong read on which way the price has been going. The weakest factor is Momentum at 46/100 — middling recent price moves. Low momentum + high trend often marks a base-building phase rather than a topping pattern.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See BIB in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent BIB news
No recent headlines name ProShares Ultra NASDAQ Biotechnology.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Funds & ETFs right now
Six funds & etfs tickers whose composite scores are closest to BIB’s 68, all within 1 point.
Sorted by closeness to BIB’s composite score within Funds & ETFs. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.